Drs. Adam Brufsky and Phuong Mai present from the San
Antonio Breast Cancer Symposium. Dr. Brufsky discusses Molecular prediction
models and Dr. Mai provides and update on breast cancer predisposition genes.
Educational objectives:
Upon completion of this activity, participants should be
able to:
- Implement proper genomic testing for breast cancer
recurrence in clinical practice.
- Follow recommendations for genomic testing for breast cancer
recurrence based on prospective clinical trials.
- Recognize the overall estimated risk level associated with
high-risk and moderate-risk breast cancer predisposition genes.
- Recognize some of the issues related to cancer panel testing
Reading Resources:
- Cardoso, et al. 70-Gene Signature as an Aid to Treatment
Decisions in Early-Stage Breast Cancer N Engl J Med 2016; 375:717-729.
- RS Jackson, et al. Distant Recurrence Rates in Groups
Defined by the AAMC Model using Grade and Hormone Receptor Status, with Comparison to
the 21-Gene Recurrence Score Groups. Breast Cancer Treat Res 2016; abstract
PD7-03.
- Sestak, I et al. Comprehensive Comparison of Prognostic
Signatures for Breast Cancer Recurrence in TransATAC Breast Cancer Treat Res
2016; abstract S6-05.
- Tung N, Domchek SM, Stadler
Z, Nathanson KL, Couch F, Garber JE, et al. Counselling framework for
moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol.
2016;13(9):581-8
- Balmana J, Digiovanni L,
Gaddam P, Walsh MF, Joseph V, Stadler ZK, et al. Conflicting Interpretation of
Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the
Prospective Registry of Multiplex Testing. J Clin Oncol. 2016;34(34):4071-8.
- National Comprehensive Cancer
Network (NCCN). Genetic/familial high-risk assessment: breast and ovarian.
Version 2.2017 [01/20/2017]. Available
from: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
Disclosures:
Dr. Mai has reported no relevant relationships with
any entities producing health care goods or services
Dr. Brufsky has financial interests with the following
any entity or entities producing health care goods or services as
indicated below:
Consultant: Agendia, Biotheranostics, nanostring, Genomic Health
All presenters disclosure of relevant financial
relationships with any entity producing, marketing, re-selling, or
distributing health care goods or services, used on, or consumed by, patients
is listed above. No other planners, members of the planning committee,
speakers, presenters, authors, content reviewers and/or anyone else in a
position to control the content of this education activity have relevant
financial relationships to disclose.
Accreditation Statement:
The University of Pittsburgh School of Medicine is
accredited by the Accreditation Council for Continuing Medical Education
(ACCME) to provide continuing medical education for physicians.
The University of Pittsburgh School of Medicine designates
this enduring material for a maximum of .75 AMA PRA Category 1 Credits™.
Each physician should only claim credit commensurate with the extent of their
participation in the activity. Other health care professionals are awarded
(0.075) continuing education units (CEU) which are equivalent to .75 contact hour.
For your credit transcript, please access our website 4
weeks post-completion at http://ccehs.upmc.edu and follow the link to the
Credit Transcript page. If you do not provide the last 5 digits of your SSN on
the next page you will not be able to access a CME credit transcript. Providing
your SSN is voluntary.
Release Date: 8/31/2017 | Last Modified On: 8/31/2017 | Expires: 8/31/2018
